Gastrointestinal Stromal Tumors (GISTs) Treatment market is expanding as molecular diagnostics and targeted therapies transform the management of this rare gastrointestinal cancer. Valued at USD 1.60 billion in 2025, the market is estimated at USD 1.73 billion in 2026 and is projected to reach USD 3.20 billion by 2034, representing an 8.0% CAGR from 2026 to 2034.
GISTs are rare mesenchymal tumors that most commonly develop in the stomach or small intestine. Treatment has evolved from primarily surgical management toward mutation-directed treatment involving tyrosine kinase inhibitors such as imatinib, sunitinib, regorafenib, avapritinib, and ripretinib.
Access the complete report:
https://www.24lifesciences.com/gastrointestinal-stromal-tumors-gsts-treatment-market-9088
Emerging Healthcare Trends Shaping Market Evolution
Molecular testing is becoming central to GIST treatment because KIT, PDGFRA, SDH-deficient, and other molecular subtypes can respond differently to available therapies.
Targeted therapy represents the dominant treatment category. Imatinib remains the standard first-line therapy for most advanced KIT/PDGFRA-sensitive disease, while subsequent therapies address resistance or specific mutations.
The development of mutation-specific treatments is also creating new market opportunities. Avapritinib is used for unresectable or metastatic GIST with PDGFRA exon 18 mutations, including D842V.
Key Market Drivers Supporting Long-Term Expansion
- Increasing diagnosis of GIST
- Expansion of molecular and genomic testing
- Growth of targeted tyrosine kinase inhibitor therapy
- Development of mutation-specific treatments
- Long-duration sequential treatment
- Growing access to generic imatinib
- Research into treatment-resistant GIST
- Expansion of oncology infrastructure in emerging markets
Drug resistance remains an important clinical challenge because tumors can acquire secondary mutations that reduce sensitivity to established therapies.
Download segment insights:
https://www.24lifesciences.com/download-sample/9088/gastrointestinal-stromal-tumors-gsts-treatment-market
Competitive Landscape: Companies Advancing GIST Treatment
The competitive landscape includes originator pharmaceutical companies, specialty oncology developers, and generic manufacturers.
- Novartis – established imatinib as a foundational targeted treatment for GIST.
- Pfizer – markets sunitinib, an established second-line treatment option.
- Bayer – markets regorafenib for later-line GIST treatment.
- Sanofi / Blueprint Medicines – brings avapritinib and its PDGFRA-mutant GIST indication.
- Ono Pharmaceutical / Deciphera Pharmaceuticals – develops and markets ripretinib for advanced GIST.
Generic competition includes Sun Pharmaceutical, Natco Pharma, Teva, Viatris, and Dr. Reddy’s Laboratories.
Segment Insights & Regional Overview
By Treatment Type, the market includes surgery, targeted therapy, radiation therapy, chemotherapy, and other treatments. Targeted therapy represents the leading market segment because KIT- and PDGFRA-directed TKIs form the foundation of systemic GIST treatment.
By Targeted Drug, the market includes imatinib, sunitinib, regorafenib, avapritinib, ripretinib, and other investigational TKIs.
By Disease Setting, localized/resectable, high-risk resected, unresectable/metastatic, and recurrent/progressive disease are covered. Unresectable/metastatic disease represents the largest systemic-treatment value.
By Molecular Subtype, KIT-mutant disease represents the largest group, while PDGFRA-mutant and other molecularly distinct GISTs create opportunities for precision therapies.
Regionally, North America leads the market, supported by molecular testing, specialist oncology access, and sequential targeted therapy. Europe has established sarcoma-center networks, while Asia-Pacific is the fastest-growing region as diagnostic infrastructure and access to targeted therapies expand. Latin America and the Middle East & Africa offer additional opportunities as specialty oncology access improves.
Explore market forecasts:
https://www.24lifesciences.com/gastrointestinal-stromal-tumors-gsts-treatment-market-9088
Technological Advancements & Strategic Outlook
Can Molecular Profiling Reshape the GIST Treatment Landscape?
Future market development will increasingly depend on genomic testing, mutation-directed therapies, circulating tumor DNA approaches, and improved treatment sequencing.
The continued challenge of acquired resistance is encouraging pharmaceutical companies to develop therapies capable of addressing specific resistance mutations. This creates opportunities for more individualized treatment pathways.
Key Benefits of the 24LifeSciences Report
- Market sizing and forecast through 2034
- Detailed treatment and drug segmentation
- Molecular subtype analysis
- Regional market assessment
- Competitive benchmarking
- Analysis of treatment sequencing
- Review of targeted therapies and emerging approaches
Download segment insights:
https://www.24lifesciences.com/download-sample/9088/gastrointestinal-stromal-tumors-gsts-treatment-market
Future Perspective
The GIST treatment market is expected to expand as molecular diagnosis becomes more integrated into treatment selection and targeted therapies extend treatment options across disease stages. Generic first-line therapy, mutation-specific medicines, and sequential later-line treatments will collectively shape the market through 2034.
About 24LifeSciences
Founded in 2017, 24LifeScience provides market intelligence and analytics for organizations operating across the global life sciences and healthcare industries, supporting strategic decisions through research covering emerging technologies, market dynamics, competitive landscapes, and growth opportunities.
Asia: +91 9425150513
Website: http://www.24lifesciences.com
